Kline JP - Search Results

1

TIGIT is a key inhibitory checkpoint receptor in lymphoma.

Godfrey J, Chen X, Sunseri N, Cooper A, Yu J, Varlamova A, Zarubin D, Popov Y, Jacobson C, Postovalova E, Xiang Z, Nomie K, Bagaev A, Venkataraman G, Zha Y, Tumuluru S, Smith SM, Kline JP. Godfrey J, et al. Among authors: kline jp. J Immunother Cancer. 2023 Jun;11(6):e006582. doi: 10.1136/jitc-2022-006582. J Immunother Cancer. 2023. PMID: 37364933 Free PMC article.

2

Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma.

Kline J, Brown IE, Zha YY, Blank C, Strickler J, Wouters H, Zhang L, Gajewski TF. Kline J, et al. Clin Cancer Res. 2008 May 15;14(10):3156-67. doi: 10.1158/1078-0432.CCR-07-4696. Clin Cancer Res. 2008. PMID: 18483384

3

Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas.

Poiré X, Kline J, Grinblatt D, Zimmerman T, Conner K, Muhs C, Gajewski T, Van Besien K, Smith SM. Poiré X, et al. Leuk Lymphoma. 2010 Jul;51(7):1241-50. doi: 10.3109/10428194.2010.486876. Leuk Lymphoma. 2010. PMID: 20496994 Clinical Trial.

4

T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse.

Kenkre VP, Horowitz S, Artz AS, Liao C, Cohen KS, Godley LA, Kline JP, Smith SM, Stock W, van Besien K. Kenkre VP, et al. Among authors: kline jp. Leuk Lymphoma. 2011 Feb;52(2):214-22. doi: 10.3109/10428194.2010.538777. Epub 2010 Dec 10. Leuk Lymphoma. 2011. PMID: 21142785 Free PMC article.

5

A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas.

Churpek JE, Pro B, van Besien K, Kline J, Conner K, Wade JL 3rd, Hagemeister F, Karrison T, Smith SM. Churpek JE, et al. Cancer. 2013 May 1;119(9):1683-9. doi: 10.1002/cncr.27917. Epub 2013 Jan 10. Cancer. 2013. PMID: 23310949 Free PMC article. Clinical Trial.

6

CD40 ligation reverses T cell tolerance in acute myeloid leukemia.

Zhang L, Chen X, Liu X, Kline DE, Teague RM, Gajewski TF, Kline J. Zhang L, et al. J Clin Invest. 2013 May;123(5):1999-2010. doi: 10.1172/JCI63980. Epub 2013 Apr 24. J Clin Invest. 2013. PMID: 23619361 Free PMC article.

7

A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.

Evens AM, Rosen ST, Helenowski I, Kline J, Larsen A, Colvin J, Winter JN, van Besien KM, Gordon LI, Smith SM. Evens AM, et al. Br J Haematol. 2013 Oct;163(1):55-61. doi: 10.1111/bjh.12488. Epub 2013 Aug 8. Br J Haematol. 2013. PMID: 23927371 Free article. Clinical Trial.

8

Peripheral T-cell tolerance in hosts with acute myeloid leukemia.

Chen X, Kline DE, Kline J. Chen X, et al. Oncoimmunology. 2013 Aug 1;2(8):e25445. doi: 10.4161/onci.25445. Epub 2013 Jul 1. Oncoimmunology. 2013. PMID: 24179704 Free PMC article.

9

PD-1 regulates extrathymic regulatory T-cell differentiation.

Chen X, Fosco D, Kline DE, Meng L, Nishi S, Savage PA, Kline J. Chen X, et al. Eur J Immunol. 2014 Sep;44(9):2603-16. doi: 10.1002/eji.201344423. Epub 2014 Aug 18. Eur J Immunol. 2014. PMID: 24975127 Free PMC article.

10

Highly clonal regulatory T-cell population in follicular lymphoma - inverse correlation with the diversity of CD8⁺ T cells.

Liu X, Venkataraman G, Lin J, Kiyotani K, Smith S, Montoya M, Nakamura Y, Kline J. Liu X, et al. Oncoimmunology. 2015 Feb 3;4(5):e1002728. doi: 10.1080/2162402X.2014.1002728. eCollection 2015 May. Oncoimmunology. 2015. PMID: 26155390 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

119 results

Search Page